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Abstract
Increasingly memory deficits are recognized in Parkinson’s disease (PD). In PD, the dopamine-producing cells of the
substantia nigra (SN) are significantly degenerated whereas those in the ventral tegmental area (VTA) are relatively spared.
Dopamine-replacement medication improves cognitive processes that implicate the SN-innervated dorsal striatum but is
thought to impair those that depend upon the VTA-supplied ventral striatum, limbic and prefrontal cortices. Our aim was to
examine memory encoding and retrieval in PD and how they are affected by dopamine replacement. Twenty-nine PD
patients performed the Rey Auditory Verbal Learning Test (RAVLT) and a non-verbal analogue, the Aggie Figures Learning
Test (AFLT), both on and off dopaminergic medications. Twenty-seven, age-matched controls also performed these memory
tests twice and their data were analyzed to correspond to the ON-OFF order of the PD patients to whom they were
matched. We contrasted measures that emphasized with those that accentuated retrieval and investigated the effect of PD
and dopamine-replacement on these processes separately. For PD patients relative to controls, encoding performance was
normal in the off state and was impaired on dopaminergic medication. Retrieval was impaired off medication and improved
by dopamine repletion. This pattern of findings suggests that VTA-innervated brain regions such as ventral striatum, limbic
and prefrontal cortices are implicated in encoding, whereas the SN-supplied dorsal striatum mediates retrieval.
Understanding this pattern of spared functions and deficits in PD, and the effect of dopamine replacement on these
distinct memory processes, should prompt closer scrutiny of patients’ cognitive complaints to inform titration of dopamine
replacement dosages along with motor symptoms.
Citation: MacDonald AA, Seergobin KN, Owen AM, Tamjeedi R, Monchi O, et al. (2013) Differential Effects of Parkinson’s Disease and Dopamine Replacement on
Memory Encoding and Retrieval. PLoS ONE 8(9): e74044. doi:10.1371/journal.pone.0074044
Editor: Jeff A. Beeler, University of Chicago, United States of America
Received May 20, 2013; Accepted July 25, 2013; Published September 26, 2013
Copyright:  2013 MacDonald et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by a Canadian Institutes for Health Research (CIHR) Clinician-Scientist, Phase 1 to Dr. Penny MacDonald. The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: penny.macdonald@gmail.com
Introduction
Parkinson’s disease (PD) is a neurodegenerative illness charac-
terized by degeneration of the dopamine-producing cells of the
substantia nigra (SN) [1]. The SN innervates the dorsal striatum,
defined as the bulk of the caudate nuclei and putamen. The
resulting dopamine depletion of the dorsal striatum in PD
produces tremor, bradykinesia, and rigidity. Dopaminergic
medications such as L-3,4-dihydroxyphenylalanine (L-Dopa) or
dopamine receptor agonists improve these motor symptoms that
typify PD [2].
Cognitive impairments are increasingly described in PD [3].
The nature and etiology of these deficits, as well as the effect of
dopaminergic medications on these processes, however, are less
clear [4–6]. Despite initial assumptions and occasional contradic-
tory findings [7,8], memory impairments are recognized in PD [9–
12]. Successful remembering depends upon effectively a) acquiring
or encoding new information and b) retrieving or accessing that
information at a later time. These processes are dissociable by
experimental manipulations [13–15]. During encoding, increased
activity in medial temporal structures (e.g., hippocampus,
perirhinal cortex) and decreased activity in regions of the default
mode network (e.g, inferior parietal cortex, precuneus) have been
shown [16–20]. In contrast, retrieval has been associated with
increased activity in posterior parietal, anterior prefrontal, and
posteromedial cortices [16,21–23]. Inconsistencies in the literature
with respect to memory performance in PD patients could owe to
the fact that most studies examine only the combined effects of
encoding and retrieval processes, in unknown proportions. Only
one previous study aimed to distinguish these separable processes
in PD [11]. Contradictory findings in PD possibly also result from
comparing studies in which PD patients are tested off relative to on
dopaminergic medication. Few studies have investigated the effect
of dopamine replacement on memory in PD [10,24] and none
have systematically examined the effect of medication on encoding
and retrieval processes separately. Hence, whether encoding and
subsequent retrieval are differentially affected by PD and
dopamine replacement remains unclear. Finally, the possibility
that memory for verbal versus non-verbal materials differs in PD
has not to this point been explored. Consequently, a comprehen-
sive study, where the same group of PD patients is investigated, on
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e74044
and off dopaminergic therapy, with both verbal and non-verbal
materials, using tests in which encoding and retrieval can be
relatively controlled and distinguished is needed.
Investigating the Effect of PD and Dopamine
Replacement on Encoding Rate and Retrieval
The aim of the current study was to clarify memory
performance in PD patients. Specifically, our aim was to
investigate encoding and retrieval in PD patients, on and off
dopamine replacement, relative to age-matched controls, using
both verbal and non-verbal materials.
Methods
Participants
Twenty-nine PD patients with an average Hoen and Yahr
staging of 1.96 (SEM 0.11) participated in the study. All patients
were evaluated in a general neurology clinic, were diagnosed by a
licensed neurologist, and met a) the core assessment program for
surgical interventional therapy criteria for the diagnosis of
idiopathic PD [25] and b) the UK Brain Bank criteria for the
diagnosis of Parkinson’s disease [26]. Twenty-seven age- and
education-matched healthy control participants were also included
in the current experiment. Patients and controls known for
dementia or mild cognitive impairment, abusing alcohol, pre-
scription or street drugs, or taking medications such as Donepezil,
Rivastigmine, Galantamine, or Memantine were excluded from
participation. Further, if patients described a change in function
related to cognitive symptoms, performed below 100 on the Adult
National Reading Test (ANART), or could not successfully draw a
clock or copy a cube, they were excluded from the study. This
study was approved by the Ethics Review Board of the Sudbury
Regional Hospital and all participants provided informed written
consent that was approved by the review board prior to testing
according to the Declaration of Helsinki [27].
Severity and presence of disease were assessed for all patients
both on and off dopaminergic medication using the motor sub-
scale of the Unified Parkinson’s Disease Rating Scale (UPDRS) by
the senior author, a movement disorders neurologist. A screening
neurological examination was performed on control participants
and none manifested signs of PD. All patients and no controls were
treated with L-Dopa. Eleven PD patients were also treated with
pramipexole, a dopamine agonist medication. This medication
constituted adjunctive therapy only, on average accounting for
25% of the daily L-Dopa medication equivalent. Mean group
demographic information, screening affective and cognitive
measures, UPDRS scores on and off medication, as well as daily
doses of dopamine-replacement therapy in L-Dopa equivalents are
presented in Table 1. Calculation of daily L-Dopa equivalent dose
for each patient was based on theoretical equivalence to L-Dopa
[28] as follows: L-Dopa dose + L-Dopa dose6 1/3 if on
entacapone + bromocriptine (mg)6 10 + cabergoline or prami-
pexole (mg)667 + ropinirole (mg)6 20 + pergolide
(mg)6100 + apomorphine (mg)6 8.
There were no statistically significant demographic differences
between PD patients and controls and all participants performed
normally on screening cognitive measures. Patients scored
significantly higher on the Beck Depression Inventory–II (BDI-
II) than controls but no participants were severely or even
moderately depressed. We used a cut-off of 28/63 on the BDI-II as
an a priori exclusion criterion but no patients approached this cut-
off. Further, there were no differences in terms of the depressive
symptoms endorsed by PD patients or controls between the on and
off sessions.
Table 1. Demographics and clinical information, as well as
screening cognitive and affective measures for PD patients
and controls.
PD Control
N 29 27
Age 63.79 (1.61) 63.78 (1.43)
Education 13.72 (0.69) 12.67 (0.59)
Years Disease 5.02 (0.99) –
LED (mg) 520 (67.32) –
DA (n) 11 –
UPDRS ON 17.19 (1.43) –
UPDRS OFF 21.76 (1.73) –
BDI-II ON 7.87 (0.99) 4.19 (0.76)
BDI-II OFF 9.80 (1.33) 4.09 (0.71)
Apathy ON 11.76 (1.31) 8.89 (1.03)
Apathy OFF 11.70 (1.26) 8.67 (1.10)
ANART IQ 120.32 (1.47) 121.40 (1.32)
F-words 13.52 (1.09) 14.22 (1.12)
A-words 10.86 (0.63) 11.20 (0.54)
S-words 13.98 (0.74) 15.30 (0.63)
Animals 18.40 (0.70) 20.94 (0.78)
Clock 3 (0) 3 (0)
Cube 1 (0) 1 (0)
WCST Categories 3.76 (0.30) 4.39 (0.27)
WCST Perseverative Errors 17.81 (1.76) 16.78 (1.47)
WCST Non-perseverative
Errors
21.03 (2.52) 15.63 (1.93)
Screening affective and cognitive measures are presented as group means
(SEM). Control participants did NOT receive dopaminergic therapy during any
session of the experiment. Their data are presented here to correspond to the
ON-OFF order of the PD patient to whom they were matched.
Education = years of education; Years Disease = years since diagnosis of
PD; LED = daily L-DOPA equivalent dose in mg; DA = number of patients
taking dopamine agonists; UPDRS ON = Unified Parkinson’s Disease Rating
Scale motor score on medication; UPDRS OFF = Unified Parkinson’s Disease
Rating Scale motor score off medication; BDI-II ON = Beck Depression
Inventory II score measured for PD patients while they were treated with their
usual dopamine-replacement therapy and for control participants during the
session that corresponded to the ON session of the PD patient to whom they
were matched; BDI-II OFF = Beck Depression Inventory II score measured for
PD patients while they abstained from their usual dopamine-replacement
therapy and for control participants during the session that corresponded to
the OFF session of the PD patient to whom they were matched; Apathy ON =
Apathy Evaluation Scale score measured during the ON session; Apathy OFF
= Apathy Evaluation Scale score measured during the OFF session; ANART IQ
= National Adult Reading Test [95] IQ estimation tested in the ON session; F-
words = average number of words beginning with the letter F generated in
one minute in ON and OFF sessions; A-words = average number of words
beginning with the letter A generated in one minute in ON and OFF sessions; S-
words = average number of words beginning with the letter S generated in
one minute in ON and OFF sessions; Animals = average number of animal
names generated in one minute in ON and OFF sessions; Clock = score on
clock drawing component of Montreal Cognitive Assessment (MOCA) tested in
the ON session; Cube = score on cube copying component of MOCA tested in
the ON session; WCST Categories = average number of correct
categorizations on the Wisconsin Card Sorting Test (WCST) in ON and OFF
sessions; WCST Perseverative Errors = average number of perseverative
errors in the WCST in ON and OFF sessions;WCST Non-perseverative Errors
= average number of non-perseverative errors in the WCST in ON and OFF
sessions.
doi:10.1371/journal.pone.0074044.t001
Dopamine and Cognition in Parkinson’s Disease
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Apparatus
The experiment was conducted on a 12.1 inch widescreen
laptop (Lenovo ThinkPad 6201) running at a resolution of
12806800 on the Windows 7 operating system. The screen was
angled for optimal viewing at a distance of approximately 50 cm.
Experimental Design and Procedure
On consecutive days, participants performed two versions of the
verbal and non-verbal memory tests described below. All patients
performed a version of each of these tests once on and once off
dopamine-replacement therapy. The ON-OFF order was coun-
terbalanced across participants, with half of the patients perform-
ing the task first ON medication and the other half performing the
first session OFF treatment. During ON testing sessions, PD
patients took their dopamine-replacement medication as pre-
scribed by their treating neurologist. During OFF testing sessions,
PD patients abstained from dopamine-replacement therapy for a
minimum of 12 and a maximum of 18 hours prior to testing.
Control participants were also tested on these memory measures
on consecutive days. Although control participants did not take
dopamine-replacement medication during either testing session,
their data were analyzed to parallel the ON-OFF order of the PD
patient to whom they were matched based on age. Controls were
matched to PD patients, and hence their ON-OFF orders were
determined, prior to testing. Therefore, we controlled for order,
fatigue, and possible practice effects.
1. Rey Auditory Verbal Learning Test (RAVLT): Verbal
Test of Explicit Memory. In each session, a version of the
main List A, consisting of 15 words, was presented to participants.
Words appeared one at a time in the centre of the computer screen
at a rate of one word per second and participants were instructed
to commit these words to memory. Immediately following the
study phase of this main list, participants were asked to write down
as many words as they could recall. This study-immediate recall
procedure for List A was repeated three times in each session.
A version of List B, also consisting of 15 words, was then
presented once with presentation parameters identical to those
described for List A. Participants immediately recalled as many
words as they could from List B, which served as an interference
event. Next, they were asked to recall as many words as they could
from the main List A. After a 30-minute delay, participants were
asked to recall as many words as they could from Lists A and B
without any further study presentations.
A recognition memory test followed. During this test, all of the
words from Lists A and B were presented, one at a time, mixed
randomly among 22 new words, in the centre of the computer
screen. Participants indicated whether the word had been
presented in the previous study phases or whether it was new,
by pressing the ‘z’ key for ‘old’ and the ‘/’ key for ‘new’
judgements. For words judged as ‘old’, participants were
additionally prompted to indicate with a key press whether the
word appeared previously in List A (i.e., ‘1’), List B (i.e., ‘2’), or
whether they were unsure of the source (i.e., ‘3’).
Appendix S1A provides Versions 1 and 2 of Lists A and B and
the new words included in the recognition tests. For all
participants, Version 1 of all lists was employed in Session 1 and
Version 2 was used in Session 2, regardless of ON or OFF
medication status. In this way, for half of the patients, Version 1
was tested on medication whereas for the remaining patients,
Version 2 was tested on medication. Control participants’ data
were analyzed to correspond to the data of the PD patient to
whom they were matched. In this way, we controlled for order,
list, fatigue, and practice effects.
2. Aggie Figures Learning Test (AFLT): Non-verbal Test of
Explicit Memory. The AFLT was entirely analogous to the
RAVLT save that abstract symbols were employed rather than
words. In brief, these abstract symbols were presented one at a
time in the centre of the computer screen for one second each.
During the recall sessions, participants were asked to draw the
abstract designs from memory, on blank sheets of paper. Further,
five study-immediate recall trials were performed rather than three
to compensate for increased difficulty in learning abstract figures
relative to common words.
Appendix S1B provides examples of designs used in the AFLT.
3. Measures of Encoding and Retrieval from Long-term
Memory. The difference in the number of items recalled from
the first to the last study-immediate recall trials in both the
RAVLT and the AFLT provided a measure of learning rate or
encoding [29,30]. We predicted, as have others, that performance
on study-immediate recall trials would be influenced, in addition
to encoding and retrieval processes, by immediate or working
memory [31,32], all in unknown proportions. Subtracting
performance on the first study-immediate recall trial from the
last, permitted measurement of the proficiency and efficiency of
learning, over repeated presentations, controlling for the effects of
immediate memory and recall abilities [31–33]. The factor that is
predicted to systematically increase across study-immediate recall
trials is the extent to which items are transferred to more long-term
memory (i.e., encoding).
In contrast, the number of items recalled on the RAVLT and
AFLT from Lists A and B following a delay, is thought to
preferentially index retrieval processes [34]. Recognition of studied
words and abstract designs from among new items, after a delay,
also was intended to stress retrieval processes [35]. Sensitivity of
recognition memory for List A and B items was estimated using d’
scores [36].
Results
Below, we report the analyses on the data for the RAVLT and
AFLT, contrasting measures that we intended to index encoding
versus to stress retrieval. For the statistical analyses, raw scores
were converted to Z-scores to avoid differences in the scale of
performance across the RAVLT and AFLT. For between-subject
analyses, raw scores were normalized within session, across groups.
For within-subject analyses, raw scores were normalized relative to
performance of each group, across sessions. Analyses performed
with raw scores produced identical patterns of results. Group
averages of raw scores reflecting learning, recall, and recognition
performance, and statistical outcomes of contrasts on these scores,
are presented in Figure 1, Panels A to C.
Encoding Measure
Learning scores were obtained separately for the RAVLT and
AFLT, as well as for each group (PD vs. Control), in each session
(ON vs. OFF). Learning scores were calculated as number of
correctly recalled items for main Lists A on the final study-
immediate recall trial (i.e., Trial 3 for the RAVLT and Trial 5 for
the AFLT) minus number of correctly recalled items on study-
immediate recall Trial 1. These scores are presented for both
groups, in each session in Table 2. Figure 1A presents the learning
scores for PD patients and controls, on the RAVLT and AFLT
combined, in the on and off sessions.
Retrieval Measures
The number of words and abstract designs recalled in the
RAVLT and the AFLT respectively from the main Lists A and the
Dopamine and Cognition in Parkinson’s Disease
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interference Lists B, following a 30-minute delay, for PD patients
and controls, in both sessions, appear in Table 3. Figure 1B
presents the average number of items recalled after delay on the
RAVLT and AFLT combined, in the on and off sessions, for both
PD patients and controls.
Sensitivity in distinguishing studied words and abstract designs
from new items, estimated by d’ scores [36] for List A and B items,
on the RAVLT and the AFLT, for PD patients and controls in
both sessions, are presented in Table 3. Figure 1C compares mean
d’ scores across sessions on the RAVLT and AFLT combined, for
PD patients and controls.
Encoding and Retrieval Between Groups
1. Encoding Measure. We performed 262 ANOVAs on
normalized learning scores, with Group (PD vs. Control) as the
between-subject factor and Test type (Verbal/RAVLT vs. Non-
verbal/AFLT) as the within-subject variable, for ON and OFF
sessions separately. Although, control participants did not take
dopaminergic medication at any point in this study, their data
were analyzed to parallel the ON and OFF session of the PD
patient to whom they were matched. We found significantly
poorer learning for PD patients relative to controls in the ON
session, F (1, 54) = 4.60, MSe =1.09, p,0.05 but no significant
group difference in the OFF session, F,1. All other main effects
and interactions were not significant, all F,1.
2. Retrieval Measures: Recall. We performed 262 ANO-
VAs on normalized recall scores, with Group (PD vs. Control) as
the between-subject factor and Test type (Verbal/RAVLT vs.
Non-verbal/AFLT) as the within-subject variable, for ON and
OFF sessions separately. The main effect of Group was significant
in the OFF session only, F (1, 54) = 6.23, MSe =1.30, p,0.025,
reflecting poorer recall for PD patients compared to controls. The
effect of Group was not significant in the ON session, F (1, 54)
= 2.72, MSe =1.33, p=0.105. In both sessions, the main effect of
Test type, F,1, and the Group x Test type interactions, F (1, 54)
= 1.16, MSe =0.58, p.0.250 and F (1, 54) = 1.36, MSe =1.36,
p.0.225, for ON and OFF respectively, were also not significant.
3. Retrieval Measures: Recognition. Analogous 262
ANOVAs, with Group (PD vs. Control) as the between-subject
factor and Test type (Verbal/RAVLT vs. Non-verbal/AFLT) as
the within-subject variable, for ON and OFF sessions separately,
were performed on normalized recognition memory scores. The
main effect of Group was significant in the OFF session only, F (1,
54) = 6.23, MSe =12.71, p,0.001, reflecting poorer recognition
memory for PD patients compared to controls. The main effect of
Group in the ON session was marginally significant, F (1, 54)
= 3.31, MSe =1.24, p=0.075, suggesting a trend toward poorer
recognition memory performance for PD patients compared to
Figure 1. Performance Scores for PD patients and Controls in
ON and OFF Sessions. Figure 1A demonstrates learning scores for PD
patients and controls in ON and OFF sessions. Mean learning scores,
calculated as total number of items recalled on the final minus the first
study-immediate recall trial, for the RAVLT and AFTL combined, are
presented for PD and controls, in both sessions separately. For PD
patients, scores in the ON medication session appear in red whereas
those for the OFF session are presented in blue. Although control
participants did NOT receive dopaminergic therapy during any session
of the experiment, their data are presented here to correspond to the
ON-OFF order of the PD patient to whom they were matched. Error bars
represent standard errors about the mean (SEM). Figure 1B demon-
strates recall performance for PD patients and controls in ON and OFF
sessions. Mean number of items recalled after delay for Lists A and B on
the RAVLT and AFLT combined, are presented for PD and control
participants, separated by session. For PD patients, scores in the ON
session appear in red whereas those for the OFF session are presented
in blue. Although control participants did NOT receive dopaminergic
therapy during any session of the experiment, their data are presented
here to correspond to the ON-OFF order of the PD patient to whom
they were matched. Error bars represent SEM. Figure 1C demonstrates
recognition memory performance for PD patients and controls in ON
and OFF sessions. Mean d’ scores for List A and B items, recognized
from newly-presented items after delay, for the RAVLT and AFLT
combined, are presented for PD and control participants, separately for
each session. For PD patients, scores in the ON session appear in red
whereas those for the OFF session are presented in blue. Although
control participants did NOT receive dopaminergic therapy during any
session of the experiment, their data are presented here to correspond
to the ON-OFF order of the PD patient to whom they were matched.
Error bars represent SEM.
doi:10.1371/journal.pone.0074044.g001
Dopamine and Cognition in Parkinson’s Disease
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controls. The effect of Test type and the Group 6 Test type
interactions in both sessions were not significant, all F,1.
4. Summary. Off medication, learning scores were compa-
rable for PD patients and control participants. On medication, PD
patients’ learning was impaired relative to that of controls. In
contrast, off medication, PD patients’ recall and recognition
memory was significantly poorer than that of controls. On
medication, PD patients’ and control participants’ recall was
equivalent, and there was only a trend toward poorer recognition
in PD patients compared to controls.
Encoding and Retrieval within Groups
1. PD Group. On PD patients’ normalized learning, recall,
and recognition scores, we performed a 36262 ANOVA, with
Experimental phase (Learning vs. Delayed Recall vs. Recognition),
Test type (Verbal/RAVLT vs. Non-verbal/AFLT), and Session
(ON vs. OFF medication) as within-subject variables. Only the
Experimental phase6Session interaction was significant, F (2, 56)
= 3.99, MSe =0.47, p,0.025. All other interactions and main
effects were not significant, all F,1.
To better understand the Experimental phase 6 Session
interaction, we examined the effect of Session on the measures
expected to index encoding and those intended to stress retrieval,
separately. First, we performed a 262 ANOVA on the normalized
learning scores with Test type (Verbal/RAVLT vs. Non-verbal/
AFLT) and Session (ON vs. OFF medication) as within-subject
variables. The main effect of Session did not reach significance, F
(1, 28) = 2.49, MSe =0.51, p=0.126. The main effect of Test type
and the Test type6 Session interaction were also not significant,
both F,1.
Next, we performed a 26262 ANOVA on the normalized
recall and recognition scores with Experimental phase (Recall vs.
Recognition), Test type (Verbal/RAVLT vs. Non-verbal/AFLT),
and Session (ON vs. OFF medication) as within-subject variables.
Only the main effect of Session was significant, F (1, 28) = 8.46,
MSe =0.30, p,0.005, reflecting poorer recall and recognition
memory scores off relative to on medication. The main effects of
Experimental Phase, Test type, and all interactions were not
significant, all F,1.
2. Control Group. Analogous ANOVAS were performed on
control participants’ normalized learning, recall, and recognition
performance scores. Again, control participants did not take
dopaminergic medication at any point in this study. However,
their data were analyzed to parallel the ON and OFF session of
the PD patient to whom they were matched. The 36262
ANOVA, with Experimental phase (Learning vs. Delayed Recall
vs. Recognition), Test type (Verbal/RAVLT vs. Non-verbal/
AFLT), and Session (ON vs. OFF medication) as within-subject
variables, revealed no significant main or interaction effects, all
F,1.
To mirror the analyses performed on PD patients’ data, we also
examined the effect of Session on the measures expected to index
Table 2. Learning in the RAVLT and AFLT for PD and control participants in both experimental sessions.
PD Control
First trial Final Learning scores First trial Final trial Learning scores
RAVLT ON 5.48 (0.32) 9.00 (0.47) 3.52 (0.43) 6.33 (0.50) 10.70 (0.45) 4.37 (0.37)
RAVLT OFF 5.14 (0.34) 9.03 (0.44) 3.90 (0.35) 6.66 (0.54) 10.59 (0.44) 3.93 (0.47)
AFLT ON 2.31 (0.31) 7.80 (0.58) 5.48 (0.44) 2.79 (0.31) 9.33 (0.66) 6.59 (0.47)
AFLT OFF 1.90 (0.25) 8.01 (0.63) 6.10 (0.54) 3.04 (0.35) 9.41 (0.64) 6.37 (0.54)
Mean number of items recalled (SEM) on the first and final immediate-recall trials in the RAVLT and AFLT are presented separately for PD and control participants in the
ON and OFF medication Sessions. Learning scores, calculated as total number of items recalled on the final minus the first study-immediate recall trial, also appear.
Scores for control participants are also displayed according to the ON-OFF order of the PD patients to whom they were matched even though no healthy controls were
treated with dopaminergic medication at any time.
doi:10.1371/journal.pone.0074044.t002
Table 3. Measures of long-term memory on the RAVLT and AFLT, for PD patients and controls, in both experimental sessions.
PD Control
Recall after delay d’ Recall after delay d’
RAVLT List A ON 6.241 (0.513) 2.171 (0.118) 7.815 (0.602) 2.473 (0.172)
List A OFF 5.931 (0.446) 2.09 (0.136) 7.889 (0.545) 2.592 (0.149)
List B ON 1.31 (0.217) 1.124 (0.113) 2.148 (0.482) 1.453 (0.172)
List B OFF 1.31 (0.244) 0.89 (0.103) 1.778 (0.46) 1.487 (0.155)
AFLT List A ON 8.379 (0.609) 2.327 (0.118) 9.074 (0.654) 2.381 (0.124)
List A OFF 7.862 (0.65) 2.256 (0.118) 9.222 (0.731) 2.606 (0.121)
List B ON 1.586 (0.327) 1.249 (0.149) 1.63 (0.321) 1.646 (0.145)
List B OFF 0.897 (0.224) 1.069 (0.152) 1.556 (0.33) 1.613 (0.144)
The mean number of items recalled out of a total of 15 for Lists A and B after delay, along with the mean d’ scores, reflecting sensitivity of old-new discriminations for
Lists A and B on both the RAVLT and AFLT are presented. Scores for PD patients appear separately for ON and OFF medication sessions. Control participants’ data are
displayed to correspond to the ON-OFF order of the PD patient to whom they were matched, although they were not treated with dopaminergic medication at any
time.
doi:10.1371/journal.pone.0074044.t003
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encoding and to stress retrieval separately for control participants.
The 262 ANOVA on the normalized learning scores with Test
type (Verbal/RAVLT vs. Non-verbal/AFLT) and Session (ON vs.
OFF medication) as within-subject variables and the 26262
ANOVA on the normalized recall and recognition scores with
Experimental phase (Recall vs. Recognition), Test type (Verbal/
RAVLT vs. Non-verbal/AFLT), and Session (ON vs. OFF
medication) as within-subject variables, both uncovered no
significant main or interaction effects, all F,1.
3. Summary. For PD patients, differences in learning
performance related to dopaminergic medication status, did not
reach significance. However, dopaminergic medication signifi-
cantly improved retrieval as assessed by delayed recall and
recognition memory performance. There were no significant
differences between ON-OFF sessions for control participants.
Discussion
Off medication, PD patients performed comparably to controls
on a measure that indexed encoding (i.e., standardized learning
difference score) but more poorly on indices that preferentially
reflected retrieval processes (i.e., standardized recall and recogni-
tion after delay). On dopamine replacement medication, learning
rate was poorer for PD patients compared to controls. In contrast,
delayed recall and recognition memory performance was im-
proved by dopamine replacement medication. This pattern of
findings arose with both verbal and non-verbal test materials. This
constitutes the first study to show dissimilar effects of dopaminergic
medication on different aspects of memory.
Most previous investigations of memory have tested PD patients
on medication only. Our findings caution that these results
represent the summed effects, in unknown proportions, of some
deficient and other spared baseline memory processes, as well as
medication-induced improvements in some operations and
impairments in others. The resulting confounded estimate of
memory performance is expected to vary across experiments with
even small methodological changes, if the contributions of
encoding and retrieval are differentially emphasized, potentially
accounting for the inconsistency of the PD memory literature
[9,12,37]. Two previous studies investigated recognition memory
both on and off medication in PD but did not attempt to dissociate
encoding and retrieval processes [10,24]. Bronnick and colleagues
[11] did test learning and retrieval independently but they only
examined medication-naive PD patients. At odds with our results,
they found impaired rate of learning for PD patients relative to
controls off medication. The reason for this discrepancy is not
entirely clear, given that we employed similar methodology.
Because we tested performance both off and on medication,
however, and observed dissociated effects of PD and medication
on learning rate versus later recall and recognition, we directly
refute their conclusion that in PD, previously-demonstrated
memory impairments are attributable to encoding deficiencies.
Specifically, we found that retrieval deficits were maximal in the
session where learning rate was equivalent for PD patients and
controls (i.e., in the OFF session). Conversely, retrieval perfor-
mance was improved in the ON session, in which learning rate
was impaired for PD patients relative to controls. Our study
constitutes the first systematic investigation of encoding and
retrieval in PD, and of the differential effect of dopamine
replacement on these separate processes.
Interpretation of Findings Related to Encoding
Functions that are normal off medication and worsened by
dopaminergic therapy in PD have been shown previously to
depend upon VTA-innervated brain regions [5,38,39]. The VTA
is relatively spared in PD, especially early in disease, and its
efferent brain regions are adequately supplied with dopamine off
medication [1]. It is hypothesized that these brain regions are
overdosed by dopamine-replacement levels that are therapeutic for
dorsal striatum-mediated motor symptoms [40]. Combining
neuroimaging and behavioural tests in PD patients on and off
medication, this overdose theory has been supported empirically.
Dopaminergic medication-related decreases have been observed in
ventral striatum [5,38], in ventromedial prefrontal cortex and
posterior insula [39], as well as in orbitofrontal cortex [38]. VTA-
innervated hippocampus, that is known to be critical for explicit
memory encoding, might also be overdosed by dopaminergic
therapy in PD, potentially accounting for our findings. This would
be in keeping with observed regulation of hippocampal-ventral
striatum-globus pallidus-mediated learning by VTA in healthy
participants [41,42].
That PD patients learned lists of words and abstract images more
poorly than controls on dopaminergic medication, but equivalently
at baseline, seems to contradict a larger literature suggesting that
dopamine improves learning in non-human animals [43,44] and
in healthy human participants [45,46]. The current experiment
differs from many of these experiments in a few important
respects. These differences and how they might account for
apparent discrepancies with respect to dopamine’s effects on
learning and memory will be discussed in the paragraphs that
follow.
First, typical learning paradigms confound learning and
performance. Proficiency of learning motor acts or skills, or of
encoding associations between stimuli and rewards, and between
stimuli and responses, is usually confirmed by asking participants
to perform the trained actions or enact decisions referring to the
learned associations. If dopamine improves skill performance or
decision making, this can simulate improved learning. Atallah and
colleagues elegantly demonstrated this fact in testing the hypoth-
esis that the dorsal striatum mediates stimulus-response and
response-reward association learning [47]. They sought to
distinguish learning these relations from performing appropriate
response selections based on what was learned. In awake and
ambulatory rats, first they compared the effect on performance in
the training session of infusing the dorsal striatum with a) a
gamma-aminobutyric acid (GABA) agonist in one group –
expected to have inhibitory effects, and b) saline in another –
expected to have no effect on dorsal striatum function. They found
that GABA infusions to dorsal striatum impaired rats’ ability to
consistently select a rewarded relative to an unrewarded arm in a
y-maze task on the basis of odour cues during the training session.
This seemed to suggest that inhibiting dorsal striatum function
impaired learning relations. However, when they stopped the
GABA and saline infusions during a later test phase, animals in the
experimental group performed equivalently to control animals.
This revealed that stimulus-response and stimulus-reward associ-
ations had been learned equally well during the training session for
both groups, but suppressing dorsal striatum function had
interfered with enactment of correct responses. Conversely, and
to drive home the point, in another experiment, when GABA
agonist versus saline infusions to the dorsal striatum were instituted
at test only, performance became impaired for the GABA group
relative to the saline group despite identical learning for both
groups during training.
A closer examination of a representative investigation of the
effect of dopamine on learning in healthy human participants
seems to echo the results of Atallah and colleagues [47]. Knecht
and colleagues [45] investigated the effect of one Levodopa/
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Carbidopa 100/25 mg tablet per day on implicit learning in
healthy adults. Participants learned to implicitly associate audito-
rily-presented pseudowords with object drawings, through trial
and error with feedback. They performed 400 learning-feedback
trials per day over five days. On Day 1 (i.e., over the course of 400
trials), there was no difference in the percentage of correct
pseudoword-drawing pairs learned by participants receiving
Levodopa versus placebo. In fact, significant differences between
groups were not evident until the end of Day 2 (i.e., at 800 trials),
when learning exceeded 70% correct. If dopamine’s role is to
facilitate learning, maximal effects would be expected during the
steepest part of the learning curve (i.e., over Days 1 and 2). In this
study, however, the effect of dopamine was greatest when learning
had reached a plateau and performance accuracy ranged between
80–90%. This pattern of findings seems more consistent with
Levodopa-mediated improvement in retrieval of pseudoword-
drawing associations than on learning these associations per se.
This revised interpretation of these results is entirely consistent
with our findings in PD patients that dopamine-replacement
medication improves retrieval.
In the current experiment, we aimed to distinguish encoding of
verbal and non-verbal materials from other influences on memory
performance. The RAVLT and AFLT methodology, with
repeated study-immediate recall events that use the same stimuli
across trials, permits a less confounded estimate of encoding
processes. Performance on each study-immediate recall trial
reflects the combined influences of word or figure encoding and
retrieval from long-term memory, as well as immediate or working
memory processes. However, the number of items transferred to
long-term memory is expected to systematically increase across
study-immediate recall trials with less clearly predictable effects on
other processes. Consequently, subtracting performance in the
final from the first stimulus-recall trial provides a less confounded
estimate of encoding or learning [31–33,48–51]. Attempting to
isolate encoding from other influences on memory is particularly
important given that immediate or working memory processes
have been shown to improve with dopaminergic medication in PD
[52–60] and in healthy young adults [61–66].
Dosages of dopaminergic medications in our study and those
investigating dopamine’s effect on learning in healthy adults differ
greatly. This is another potentially important difference. In the
current study, the average daily Levodopa equivalent was 520 mg
compared to 100 mg in the study performed by Knecht and
colleagues [45]. PD patients are also arguably more susceptible to
overdose effects from exogenous dopaminergic medications
because dopamine-producing neurons also regulate synaptic
dopamine [67]. As these cells are lost in PD, so is dopamine
buffering capacity.
Although our result of poorer learning for PD patients on
dopaminergic medication relative to healthy control participants
might on the surface seem at odds with findings in non-human
animals and healthy human participants, it is entirely in keeping
with findings in PD. Our results, however, extend the learning
situations that are impaired by dopaminergic medication to
include intentional and explicit encoding of word and image lists.
That is, in PD, learning is the function most frequently worsened
by dopamine replacement therapy [68–73]. A number of studies
have revealed deficits related to dopamine replacement medica-
tions in probabilistic associative learning in PD patients who
perform equivalently to controls off medication [69,72,74].
Shohamy and colleagues [71] found that dopaminergic medica-
tion impaired learning of an incrementally-acquired, concurrent
discrimination task, whereas off medication, PD patients per-
formed as well as controls. Sequence learning was reduced for PD
patients on medication [68,70,75,76]. Dopamine supplementation
yielded reduced facilitation for consecutive, consistent stimulus-
stimulus pairings in a selection task compared to normal
facilitation when PD patients were tested off medication [4].
Once stimulus-reward associations have been learned, reversing
these associations is also performed more poorly for PD patients
on dopamine replacement therapy [6,77–83]. Dopamine therapy
has been shown to impair learning from negative feedback [84].
Finally, there are a number of studies with healthy adults in
which dopaminergic therapy has led to diminished learning.
Breitenstein and colleagues [85] found that administering a
dopamine agonist significantly impaired novel word learning in
healthy volunteers compared to placebo. Similarly, Pizzagalli and
colleagues [86] and Santesso and colleagues [87] found that
reward learning was impaired in healthy adults after pramipexole
was administered.
Interpretation of Findings Related to Retrieval
The SN, which is significantly degenerated at even the earliest
stages of clinical PD, has dopamine projections nearly exclusively
to the dorsal striatum. Hence, the pattern of baseline deficits in
early PD that are remediated by dopamine supplementation in PD
is the signature of a dorsal striatum-mediated process. In our
study, PD patients were impaired at baseline but improved with
dopamine replacement on all measures that stressed retrieval, even
though encoding was impaired in PD patients relative to control in
the on session. Our results are consistent with a role for dorsal
striatum in retrieval. A review of the literature reveals evidence in
line with these findings.
Surveying cognitive deficits in patients with dorsal striatum
lesions in fact reveals that the most common impairment is in
explicit memory [88–90]. In functional neuroimaging studies,
dorsal striatum is preferentially activated for learned relative to
random motor sequences [91], for familiar items in an episodic
recognition test [20], and while recalling recently-learned category
membership [92,93]. Unlike activity in ventral striatum that tracks
the progression of learning, dropping off as performance
asymptotes and hence learning plateaus [4,91,93], preferential
activation of the dorsal striatum in neuroimaging studies persists
well after sequences or categorization rules [93] have been
encoded. Together these findings suggest that although dorsal
striatum is implicated in explicit memory function, it does not
underlie learning or encoding processes. Based on our data, we
posit that it mediates retrieval of previously encoded information.
Conclusion
Increasingly, cognitive impairment is identified as a significant
cause of disability in PD [94]. The nature and pathophysiology of
cognitive deficits in PD are not fully understood. Enhanced
understanding of these impairments and the effect of dopamine
replacement therapy on cognition in PD is an important aim as it
will translate directly into improved clinical care. Here we show
that learning rate and retrieval processes are oppositely affected by
PD and dopaminergic medication. Whereas encoding rate is
spared at baseline in PD, successful retrieval from long-term
memory is impaired. On dopaminergic medications, PD patients
encoded both verbal and non-verbal information more poorly
than controls whereas dopamine replacement improved later
retrieval from long-term memory. These findings shed light on the
memory literature in PD and subsequent studies will aim to better
understand the brain regions that mediate these findings. More
specific understanding of memory impairments in PD might guide
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clinicians to consider a broader range of symptoms and tailor
medication strategies to specific patient complaints and priorities.
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